Navigation Links
Folic acid retards mental decline in middle aged

Folic acid or Vitamin B9 has been known to help in the brain development of foetus and infants for a //long time now. Due to this reason it is administered to pregnant women. A new study conducted by scientists at Wageningen University, Netherlands has proposed that this vitamin can slow down the cognitive decline in middle-aged subjects.

The three year long study involved 818 subjects (both men and women) with increased levels of homocysteine. This amino acid present in blood, has been shown to be associated with heart disease and stroke The study group was administered 800 micrograms of folic acid or a placebo for the entire study period.

After the test data was analysed it was found that those who received folic acid showed 5.4 years younger in memory, 2.0 years younger in information processing, and 1.9 years younger in sensory motor speed compared with those who received a placebo. This can be especially useful when treating patients with Alzheimer’s disease. The role of vitamins B6 and B12 are also being investigated for reducing the level of homocysteine in blood.


'"/>




Page: 1

Related medicine news :

1. Folic Acid helps Kids with Diabetes
2. Folic Acid Found To Be Beneficial For Stroke Patients
3. The Importance Of Folic Acid Supplements
4. Folic Acid Supplementation During Pregnancy Could Help Prevent Spina Bifida
5. Folic Acid and Vitamin B12 Effective In Reducing The Risk Of Hip Fracture After Stroke
6. Folic Acid Retards Mental Decline In Middle Aged Subjects
7. Study Links Folic Acid With Increased Birth Weight
8. Folic Acid blows Gene-based Colon Cancer
9. Dietary supplementation of Folic Acid Requires Critical Evaluation
10. Folic acid enriched grain reduces birth defects
11. Addition Of Folic Acid In Flour Proposed To Arrest Birth Defects In The UK
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” Pate ... year donated money to the Triumph Over Kid Cancer foundation. Each year, 175,000 children ... those children. James saw firsthand the effect of the critical funding gap for research ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) ... a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background in ... “It is with considerable pleasure to welcome back Dr. Kim to the CDG team” ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from ... in breast surgery. Covering topics from cosmetic breast augmentation to breast ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... From a ... are released almost daily linking gut health to chronic disease, mental health and general ... Year ” as an important resolution to consider. , For one Charlottesville restaurant, good ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced ... to compete in the Boston Marathon on April 17. From first-time participants to ... marathon to join Team V and support the Foundation’s mission to declare victory over ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 The Philadelphia Pediatric Medical ... developing medical devices for children. The Consortium chose ... seed grants of $50,000 each. The devices under ... nerve signals, a hand-operated rapid blood delivery system for emergency ... babies. ...
(Date:1/18/2017)...   Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to restore ... the Company,s operating results for 2016 and an outline ... Company described in its recent 10-K filing with the ... The Company,s contract laboratory completed its evaluation of NovaDerm®, ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: